Tom Laundon is an, experienced executive with demonstrated accomplishments in capital allocation, finance, accounting, financial reporting, legal, operations, marketing and business development in small to medium enterprises. He has particular expertise in technology-oriented organizations that are privately owned and/or financed through institutional venture capital. Most recently, Mr. Laundon served as interim CFO for Innocrin Therapeutics in its successful spinout from Viamet, Inc. He also served as CFO for G1 Therapeutics and as COO for ArtusLabs, Inc. (acquired by Perkin-Elmer, PKI), PhaseBio Pharmaceuticals and Synthematix (acquired by Symmx, SMMX). Mr. Laundon was the first Vice President for Economic Development at the North Carolina Biotechnology Center. Mr. Laundon has served on the Executive Committee and Board of NC BIO and on the Board of Directors of IssueTrak as well as the Council for Entrepreneurial Development. He is a member of the National Association of Corporate Directors (NACD). Mr. Laundon graduated with a B.S. in Industrial Engineering from NC State University and an MBA from Harvard Business School.